Synergy of piracetam and aminalon in the cerebroprotective effect of olatropyl.
DOI:
https://doi.org/10.26641/2307-0404.2018.3.147945Ключевые слова:
piracetam, gamma-aminobutyric acid, olatropil, synergismАннотация
Optimization of pharmacotherapy of neurological and psychosomatic diseases led to the creation of combined medicines containing two or more components with different mechanisms of action, differently affecting the pathogenesis and clinical manifestations of specific forms of pathology. Combined drugs that help normalize the central regulatory mechanisms of the development of somatic pathology, improve brain metabolism and hemodynamics, stabilize the cortical-subcortical relationships, the disorders of which lie at the base of many forms of neurological and psychosomatic pathology have been particularly popular in recent years. In this article we propose options for optimizing nootropic therapy with olatropyl, which is a combination of two "true" nootropics - gamma-aminobutyric acid (aminalone) and piracetam in one drug form. Such a combination allows one-stage implementation of a complex of multifaceted and diverse effects on the central nervous system characteristic of both piracetam and aminalone, but achieved through fundamentally different mechanisms of action of these agents. The mechanism of action of olatropil demonstrates the pronounced synergism of the monocomponents of the preparation. This combination allows to reduce the therapeutic dosages of each of the active substances by 2 times, which, in turn, leads to a decrease in the incidence and severity of possible side effects; leveling the exciting effect of piracetam and providing higher safety and efficacy. The drug is an effective tool for the therapy of various forms of cerebrovascular pathology, improving cognitive functions, mental activity, psychoemotional status, autonomic functions, favorably affecting the quality of life of patients. The uniqueness of the mechanism of action of olatropil, consisting in the occurrence of the fact of pharmacodynamic synergy in the combined use of piracetam and aminalone in a single dosage form, contributes to the enhancement of positive pharmacological effects and the leveling of a number of negative elements of pharmacodynamics of preparation constituents.Библиографические ссылки
Antipchuk EYu, Loganovskii KN, Chuprovskaya NYu, Bomko MA, Loganovskaya TK, Denisyuk NV, Kolosinskaya EA, Chumak SA, Krejnis GYu, Perchuk IV, Zdorenko LL, Kravchenko VI, Zdanevich NA, Vasilenko ZL, Drozdova NV, Yuhimenko EN, Gres'ko MV. [Olatropil in the treatment of cognitive impairment in victims of the Chernobyl disaster]. Ukrayinskyi nevrologichnyi zhurnal. 2007;3:75-81. Russian.
Arushunyan E.B. [Nontraditional approach to the assessment of the mechanism of the specific action of nootropic agents]. Eksperimentalnaya i klinicheskaya farmakologiya. 2008;68(2):59-67. Russian.
Burchynskyi SG. [Issues of analgesic effects of nootropic drugs: noofen preparation]. Liky. 2005;5-6:10-14. Ukrainian.
Burchinskyi SG. [Clinical and pharmacological criteria for assessing the safety of nootropic drugs]. Mezhdunarodnyi nevrologicheskii zhurnal. 2015;3(73):77-84. Russian.
Burchinskyi SG. [Nootropic and vasotropic pharmacotherapy in neurology: a combination of drugs or a combined effect?]. Mezhdunarodnyi nevrologicheskii zhurnal. 2015;7(77):133-38. Russian.
Burchynskyi SG. [Olatropil – a new combined nootropic drug]. Medicni perspektivi. 2006;11(4):53-56. Ukrainian.
Burchinskyi SG, Gonchar OYu, Rajchenko KV. [The problem of the safety of nootropic pharmacotherapy in neurological practice]. Mezhdunarodnyi nevrologicheskii zhurnal. 2017;7(93):56-60. Russian.
Voronina TA, Seredenin SB. [Nootropic and neuroprotective agents]. Ehksperimentalnaya i klinicheskaya farmakologiya. 2007;70(4):44-58. Russian.
GolikVA.[Renaissance of nootropic therapy: from the beginnings to new areas of clinical use of nootropics in diseases of the central nervous system]. Neiron-revyu. 2012;3:2-22. Russian.
Damulin IV, Koberskaya NN, Savushkina IYu. [Using olatropil for dyscirculatory encephalopathy]. The Journal of Neuroscience of BM Mankovsky. 2014;2(2):37-9. Russian.
Kovalyov GI, Kondrahin EA, Salimov RM, Neznamov GG. [Effect of piracetam on the behavior and receptors of the brain of C57BL / 6 and BALB / c mice – nootropic and anxiolytic effects]. Eksperimentalnaya i klinicheskaya farmakologiya. 2013;76(9):3-10. Russian.
Evtushenko ES. [Nootropics and neuroprotectors in modern clinical neuropharmacology]. Mezhdunarodnyi nevrologicheskii zhurnal. 2013;3(57):20-27. Russian.
Zhiliuk VI, Mamchur VI. [The role of endothelium in the action of nootropics in cognitive impairment due to chronic hyperglycemia]. Zhurnal Nacionalnoi akademii medychnyh nauk Ukrainy. 2013;9(2):184-93. Russian.
ZupanecIA,ShebekoSK,OtrishkoIA.[Pharmacodynamic aspects of neuroheroprotective synergism of the drug "Olatropil"]. Ukrayinskyi visnyk psyhonevrologii. 2016;24(87):113-6. Russian.
Kadykov AS Manvelov LS,ShahparonovaNV. [Chronic vascular diseases of the brain (circulatory encephalopathy)]. Moskva, GEHOTAR-Media. 2006;224. Russian.
Kovalev GI, Firsova YuYu,SalimovRM.[Effect of piracetam and atsaphen on NMDA and nicotinic receptors in the brain of mice with different efficacy of exploratory behavior in the crucious maze]. Eksperimentalnaya i klinicheskaya farmakologiya. 2008;71(1):12-7. Russian.
Mamchur VI, Zhiliuk VI, Dronov SN, Kravchenko KA, Krauz VA. [Pharmacology of cerebroprotectors in the form of fixed combinations]. Materials of the III Congress of pharmacologists ofRussia"Pharmacology - practical health care". 2007;2-1847. Russian.
Morozova OG, Yaroshevskij AA, Lipinskaya YaV. [The effect of olatropil on cognitive, autonomic and psychoemotional indicators in patients with chronic cerebral ischemia against arterial hypertension]. Mezhdunarodnyi nevrologicheskii zhurnal. 2015;3(73):61-70. Russian.
Ostroumova OD, Vatutina AM, Zykova AA. [Drug interactions: are there “ideal” drugs for use in polypragmasia?]. Russkii medicinskii zhurnal. 2003;11(21):11-21. Russian.
Belenichev IF, Chernii VI, Kolesnik YuM. [Rational Neuroprotection]. Doneck, Izdatel Zaslavskii AYu. 2009;262. Russian.
Vengerovskii AI. [Pharmacology. Course of lectures: study guide]. Moskva, GEHOTAR-Media. 2015;736. Russian.
Firsova YuYu, Dolotov OV, Kondrahin EA, Dubynina EV, Grivennikov IA, Kovalev GI. [The effect of nootropic drugs on the level of BDNF in the hippocampus and the cerebral cortex of mice with different research behavior efficacy]. Eksperimentalnaya i klinicheskaya farmakologiya. 2009;72(6):3-6. Russian.
Homazyuk TA, Krotova VYu. [Problems of cognitive impairment and medical rehabilitation in polymorbid pathology in the elderly]. Neurology and neurosurgery.Eastern Europe. 2017;7(3):530-42. Russian.
Yarosh OK, Dudko OT, Gromov LO. [Clinical-experimental assessment of cerebroprotective action of olatropil]. Klinichna farmaciia. 2005;11:12-7. Ukrainian.
Halff AW, Gómez-Varela D, John D, Berg DK. A novel mechanism for nicotinic potentiation of glutamatergic synapses. J. Neurosci. 2014;34(6):2051-64.
DiMasi JA, Grabowski HG, Hansen RW. The cost of drug development. N. Engl. J. Med. 2015;372(20):1972.
Ellergast JP. Gamma-aminobutyric acid – mediated neurophysiological effects in the central nervous system. Brain neurophysiology.Chicago,IllinoisUniv. Press. 2000;497-530.
Flicker L. Piracetam. Evidence-based Dementia Practice. Ed. by N.Qizilbash et al.Oxford, Blackwell Publishing. 2002;546-8.
Frisch SM, Screaton RA. Anoikis mechanisms. Curr. Opin. Cell. Biol. 2001;13:555-62.
Hawkins BT,DavisTP. The blood-brain barrier / neurovascular unit in health and disease. Pharmacol. Rev. 2005;57:173-85.
Hock C. Biochemical aspects of dementia. Dial. Clin. Neurosci. 2003;5:27-34.
Banks PJ, Warburton EC, Brown MW, Bashir ZI. Mechanisms of synaptic plasticity and recognition memory in the perirhinal cortex. Prog. Mol. Biol. Transl. Sci. 2014;122:193-209.
Enciu AM, Nicolescu MI, Manole CG, Mureşanu DF, Popescu LM, Popescu BO. Neuroregeneration in neurodegenerative disorders. BMC Neurol. 2011;11(1):75-81.
Collingridge GL, Volianskis A, Bannister N, France G, Hanna L, Mercier M, Tidball P, Fang G, Irvine MW, Costa BM, Monaghan DT, Bortolotto ZA, Molnár E, Lodge D, Jane DE. The NMDA receptor as a target for cognitive enhancement. Neuropharmacology. 2013;64:13-26.
Zhang J, Li Y, Xu J, Yang Z. The role of N-methyl-D-aspartate receptor in Alzheimer's disease. J Neurol. Sci. 2014;339(1-2):123-9.
Muresanu DF, Buzoianu A., Florian SI, von Wild T. Towards a roadmap in brain protection and recovery. J. Cell. Mol. Med. 2012;16(12):2861-71.
Winblad B. Piracetam: A review of pharmacological properties and clinical uses. CNS Drug Rev. 2005;11:169-82.
Загрузки
Как цитировать
Выпуск
Раздел
Лицензия
Copyright (c) 2018 Medicni perspektivi (Medical perspectives)
Это произведение доступно по лицензии Creative Commons «Attribution» («Атрибуция») 4.0 Всемирная.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
